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rimary cervical cancer screening
a  b  s  t  r  a  c  t
Background:  AnyplexTM II HPV  HR  Detection  (Seegene,  Seoul,  Korea)  is a multiplex  real-time  PCR using
tagging  oligonucleotide  cleavage  and  extension  (TOCE)  technology  for simultaneous  detection  and  geno-
typing  of  14  high-risk  (HR)  HPV  types,  including  HPV16  and  HPV18.
Objectives:  To evaluate  whether  the  clinical  performance  and  reproducibility  of AnyplexTM II HPV  HR
Detection  meet  the  international  consensus  guidelines  for HPV  test  requirements  for  cervical  cancer
screening  [1].
Study design:  The  clinical  performance  of  AnyplexTM II HPV  HR  Detection  for detecting  cervical  intraep-
ithelial  neoplasia  grade  2  or worse  (CIN2+)  was  determined  relative  to that of the  reference  assay,  i.e.,  HR
HPV GP5+/6+-PCR-EIA,  by  analysis  of a total  of 879  cervical  liquid  based  cytology  (LBC)  specimens  from
a  screening  population,  of  which  60  were  from  women  with  CIN2+.  The  intra-laboratory  reproducibility
and  inter-laboratory  agreement  were  determined  on 509 LBC  samples,  of which  172 were  positive  by the
reference  assay.
Results: AnyplexTM II HPV  HR  Detection  showed  a  clinical  sensitivity  for CIN2+  of  98.3% (59/60;  95%
CI:  89.1–99.8)  and  a clinical  speciﬁcity  for CIN2+  of  93.6%  (764/816;  95%  CI: 89.8–96.1).  The clinical
sensitivity  and  speciﬁcity  were  non-inferior  to  those  of  HR  HPV  GP5+/6+-PCR-EIA  (non-inferiority  score
test:  P  =  0.005  and  P  =  0.023,  respectively).  Both  intra-laboratory  reproducibility  (96.8%;  95%  CI:  95.3–98.1;
kappa  value  of  0.93)  and  inter-laboratory  agreement  (96.0%;  95%  CI:  94.3–97.4;  kappa  value of  0.91)  were
high.
Conclusions:  AnyplexTM II HPV  HR  Detection  performs  clinically  non-inferior  to  HR  HPV  GP5+/6+-PCR-EIA.
AnyplexTM II HPV  HR Detection  complies  with  international  consensus  validation  metrics  for  HPV  DNA
tests  for  cervical  cancer  screening  [1].
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Background
HPV testing is increasingly considered for primary cervical
ancer screening. To ensure high-quality screening, clinical utility
f HPV assays has to be demonstrated. In 2009, an international
onsortium proposed criteria for assay validation in primary
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screening context based on minimal relative clinical accuracy of a
given HPV assay compared to a clinically validated reference (i.e.,
Hybrid Capture 2 or high-risk (HR) HPV GP5+/6+-PCR-EIA), and
minimal intra- and inter-laboratory reproducibility [1,2]. Several
HPV assays have partially or completely been clinically validated
using these criteria [3]. An assay not yet evaluated according to
these international consensus validation metrics is AnyplexTM II
HPV HR Detection (Seegene, Seoul, Korea). AnyplexTM II HPV HR
Detection comprises an automated system from specimen han-
dling to HPV result, including an automated instrument Microlab
Nimbus IVD or STARlet (Hamilton) for DNA isolation and real-time
PCR setup, subsequent HPV testing with CFX96 PCR instrument
(Bio-Rad), and data analysis with Seegene Viewer (Seegene).
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he multiplex real-time PCR design using tagging oligonucleotide
leavage and extension (TOCE) technology allows for simultaneous
etection and genotyping of 14 high-risk (HR) HPV types, including
PV16,−18,−31,−33,−35,−39,−45,−51,−52,−56,−58,−59,−66,
nd  −68 (L1 gene), and an internal control (human beta-globin) in
 single reaction [4].
. Objective
The current study was set out to determine whether AnyplexTM
I HPV HR Detection meets the international guidelines for primary
creening [1] by comparing its clinical sensitivity and speciﬁcity for
ervical intraepithelial neoplasia grade 2 or worse (CIN2+) to that
f the reference HR HPV GP5+/6+-PCR-EIA (further referred to as




For clinical sensitivity analysis, a representative set of 60 cervical
iquid based cytology (LBC) samples (PreservCyt) from women par-
icipating in population-based screening in the Netherlands, who
ere diagnosed with histologically conﬁrmed CIN2+, were used.
hese comprised 25 CIN2, 31 CIN3, and 4 squamous cell carcino-
as. The median age of the women was 40 years (range 30–60
ears). These clinical cases were detected on the basis of an abnor-
al  cytology result and/or a positive result by GP5+/6+-PCR [5].
he samples of 43 (72%) of these women revealed abnormal cytol-
gy (5 borderline or mild dyskaryosis (BMD) and 38 >BMD), 17
28%) had normal cytology, and all but one (98.3%) were positive
y GP5+/6+-PCR.
For clinical speciﬁcity analysis, we used 819 consecutively col-
ected LBC samples (PreservCyt) from the screening population of
omen (median age of 41 years, range 31–60 years) with normal
ytology and without evidence of CIN2+ within 2 years of follow-up.
Intra-laboratory reproducibility and inter-laboratory agree-
ent of AnyplexTM II HPV HR Detection were evaluated using
hree equal portions of in total 509 cervical PreservCyt samples,
f which one-third was positive by GP5+6+-PCR (172/509; 33.8%).
wo portions were tested in a blinded manner within the same
aboratory (Lab A; VU University Medical Center, Amsterdam, The
etherlands) by different technicians at different time points. The
hird set was analyzed blinded for the results of lab A, at another
aboratory (Lab B; Institute of Microbiology, CHUV, University of
ausanne, Lausanne, Switzerland).
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a Input in PCR comprising 1/650 fraction of the cervical scrape.
b DNA was extracted from cervical scrapes using the Nucleo-Mag 96 Tissue kit (Ma
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All LBC samples were stored in aliquots at −80 ◦C until further
use.
3.2. AnyplexTM II HPV HR Detection
AnyplexTM II HPV HR Detection comprising DNA extraction,
HPV testing and data analysis, was performed according to the
manufacturer’s instructions (Seegene, Seoul, Korea). In short, up
to 40 clinical samples per run were processed by the automated
system with a laboratory working time from specimen handling
to HPV result of approximately 6 h (i.e., 2 h for DNA extraction,
3 h 40 min  for PCR ampliﬁcation with three melting analyses, and
hands-on time of 15–20 min  for specimen handling and 10 min for
PCR machine handling).
3.3. Statistical analyses
AnyplexTM II HPV HR Detection was performed blinded for ear-
lier obtained GP5+/6+-PCR-EIA results [5] and cyto-/histopathology
outcomes, and data were correlated afterwards. Clinical sensitivity
and speciﬁcity values for CIN2+ of AnyplexTM II HPV HR Detec-
tion were compared to those of GP5+6+-PCR using a non-inferiority
score test, as described by Tang et al. [6], with a relative sensitivity
threshold for CIN2+ of 90% and a relative speciﬁcity threshold for
CIN2+ of 98% as proposed in the consensus guidelines [1]. For intra-
laboratory and inter-laboratory analyses, the agreement and kappa
values were determined. The 95% lower conﬁdence bounds of the
intra-laboratory reproducibility and inter-laboratory agreement
values should be ≥87%, with kappa values of ≥0.5. Only samples
with valid test results were included in the analyses. The level
of genotype agreement was determined by using kappa statistic.
Association between semi-quantitative viral load values (based on
signal intensity scores +, ++, or +++), and discordance was  evaluated
with chi-square test for trend. The level of statistical signiﬁcance
was set at 0.05.
4. Results
4.1. Clinical sensitivity and clinical speciﬁcity
Of the 879 cervical LBC samples for clinical sensitivity and speci-
ﬁcity analyses, 876 (99.7%) revealed valid results with AnyplexTM
II HPV HR Detection. Agreement between AnyplexTM II HPV HR
Detection and GP5+6+-PCR was high. All 60 samples of women with
CIN2+ (100%; 95% CI: 94.0–100;cases) and 788 of 816 samples of
the speciﬁcity set (96.6%; 95% CI: 93.3–98.3;controls) showed an
identical outcome with both tests (Table 1).












cherey–Nagel, Germany) and Microlab Star robotic system (Hamilton, Germany)
on of the cervical scrape.
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Table 2A
Intra-laboratory reproducibility over time of AnyplexTM II HPV HR Detection.
Lab A, result run 1 Lab A, result run 2
HR HPV negative HR HPV positive Total
HR HPV negative 334 9 343
HR  HPV positive 11 151 162
Total 345 160 505
Table 2B
Inter-laboratory agreement of AnyplexTM II HPV HR Detection.
Lab B Lab A, result run 1a
HR HPV negative HR HPV positive Total
HR HPV negative 336 8 344
HR  HPV positive 8 153 161






































Intra-laboratory reproducibility of genotype ﬁndings of AnyplexTM II HPV HR
Detection.
HR HPV type Number of samples found positive bya Kappa 95%CI
Both runs Run 1 only Run 2 only
16 49 6 2 0.92 0.86–0.97
18  20 1 3 0.91 0.82–1.00
31  17 2 4 0.84 0.72–0.97
33  12 0 0 1.00 –
35  6 1 0 0.92 0.77–1.00
39  11 6 6 0.64 0.44–0.83
45  3 1 5 0.50 0.15–0.84
51  15 2 1 0.91 0.80–1.00
52  17 1 1 0.94 0.86–1.00
56  14 1 4 0.84 0.71–0.98
58  7 0 3 0.82 0.62–1.00
59  5 1 1 0.83 0.60–1.00
66  12 1 0 0.96 0.88–1.00
68  12 0 3 0.89 0.76–1.00
a Data are presented as the number of each genotype detected in each run (i.e.,
run 1 and/or run 2), and numbers do not count up to the total number of HR HPV
positive samples due to multiple infections.
Table 3B
Inter-laboratory agreement of genotype ﬁndings of AnyplexTM II HPV HR detection.
HR HPV type Number of samples found positive bya Kappa 95% CI
Both labs Lab 1 only Lab 2 only
16 51 3 3 0.94 0.89–0.99
18  21 0 2 0.95 0.89–1.00
31  19 0 3 0.92 0.84–1.00
33  11 1 0 0.96 0.87–1.00
35  7 0 0 1.00 –
39  11 5 5 0.68 0.49–0.87
45  3 1 4 0.54 0.18–0.90
51  16 1 1 0.94 0.85–1.00
52  16 2 0 0.94 0.85–1.00
56  14 1 8 0.75 0.59–0.91
58  7 0 2 0.87 0.70–1.00
59  6 0 1 0.92 0.77–1.00
66  12 1 2 0.89 0.76–1.00
68  11 1 2 0.88 0.74–1.00
a Data are presented as the number of each genotype detected at each location
(i.e., laboratory 1 and/or 2), and numbers do not count up to the total number of HR
HPV  positive samples due to multiple infections.a Similar results were obtained when using results of run 2 from Lab A: agreement
f  96.2% (95% CI: 94.6–97.6) with a kappa value of 0.91.
AnyplexTM II HPV HR Detection was positive for 59 women
ith CIN2+, resulting in a clinical sensitivity for CIN2+ of 98.3%
59/60; 95% CI: 89.1–99.8) (Table 1, cases). The clinical speciﬁcity
or CIN2+ was 93.6% (764/816; 95% CI: 89.8–96.1) (Table 1, con-
rols). By comparison, these ﬁgures were 98.3% (59/60; 95% CI:
9.1–99.8) and 94.1% (768/816; 95% CI: 90.3–96.5), respectively,
or GP5+/6+-PCR (Table 1). Both clinical sensitivity and speciﬁcity
or CIN2+ of AnyplexTM II HPV HR Detection were non-inferior to
hat of GP5+6+-PCR, i.e., relative clinical sensitivity for CIN2+ of
.00 (P = 0.005) and relative clinical speciﬁcity for CIN2+ of 0.99
P = 0.023).
.2. Intra-laboratory reproducibility and inter-laboratory
greement
Of the 509 samples, 506 (99.4%) had a valid test result in run 1 at
ab A, 507 (99.6%) in run 2 at lab A, and one sample had insufﬁcient
aterial left for testing at lab B, leaving 505 samples with valid data
or both intra-and inter-laboratory analyses. The intra-laboratory
eproducibility over time was 96.0% (485/505; 95% CI: 94.3–97.4),
ith a kappa value of 0.91 (Table 2A).
The inter-laboratory agreement was 96.8% (489/505; 95% CI:
5.3–98.1), with a kappa value of 0.93 (Table 2B).
Both the intra-laboratory reproducibility over time and the
nter-laboratory agreement fulﬁlled the validation metrics given
 lower conﬁdence bound of percentage of agreement that was
igher than 87%, and a corresponding kappa value that was  higher
han 0.5 [1]. Most samples with discrepant ﬁndings (18/20 in intra-
ab and 13/16 in inter-lab analysis) had low signal intensity (score
), suggesting association of discrepant results with low viral loads
P = 0.0008 and P = 0.007, respectively).
At the genotype level, moderate to perfect agreement was
bserved, with overall kappa of 0.87 (range: 0.50–1.00) and 0.89
range: 0.54–1.00) for intra-and inter-laboratory genotyping agree-
ent, respectively (Tables 3A and 3B ). Discrepant results at the
ype-speciﬁc level, that were most commonly found for HPV39
nd HPV45, mostly concerned multiple infections and low signal
ntensities for respective types.
. ConclusionsIn this study, we compared the clinical performance of
nyplexTM II HPV HR Detection with that of GP5+6+-PCR in a cohort
f screening participants. The clinical sensitivity and speciﬁcity for
IN2+ of AnyplexTM II HPV HR Detection were non-inferior to thoseof GP5+6+-PCR using the predetermined thresholds of 90% and
98%, respectively, as set out by the international consortium [1].
Furthermore, the assay displayed sufﬁcient intra-laboratory repro-
ducibility and inter-laboratory agreement, both complying with the
international consensus validation metrics for HPV DNA tests for
cervical cancer screening [1]. Based on our ﬁndings, AnyplexTM II
HPV HR Detection can be added to the list of HPV assays that fulﬁll
the 2009 guidelines [3].
AnyplexTM II HPV HR Detection adds to some other validated
assays [3] that it directly provides genotyping data of 14 HR HPV
types. Genotyping data turned out to be highly reproducible in this
study as well, with moderate to perfect agreement. Although at
present genotyping of non-HPV16/18 types is in the current guide-
lines not recommended for primary cervical screening, it may  be
useful in the future for measuring persistence of a speciﬁc HR HPV
type in certain setting (e.g., post-treatment monitoring of women
treated for high-grade CIN).
In conclusion, this study demonstrates that AnyplexTM II HPV HR
Detection is clinically non-inferior to GP5+/6+-PCR. The clinical per-




















in:  C.E. Davy, J. Doorbar (Eds.), Method in Molecular Medicine; HumanA.T. Hesselink et al. / Journal o
riteria for validation of an HPV test for cervical cancer screening
urposes [1].
unding
This research was supported by a grant from Seegene. The source
f funding did not have any inﬂuence on the design and the analysis
f the results.
thical approval
This study followed the local ethical guidelines of VU University
edical Center.
ompeting interests
ATH and MLS  are employees of Self-screen B.V. DAMH and PJFS
ave minority stake in Self-screen BV, a spin-off company of VU
niversity Medical Center. DAMH has been on the speaker’s bureau
f Hologic/Gen-Probe and serves occasionally on the scientiﬁc advi-
ory boards of AMGEN and Pﬁzer. JB has received consultancy or
peaker fees from Qiagen, Roche, DDL, Merck and GSK. PJFS has
[cal Virology 76 (2016) 36–39 39
been on the speaker’s bureau of Roche, Abbott, Gen-Probe, Qia-
gen and Seegene. He is consultant for Crucell Holland B.V. All other
authors declare that they have no conﬂict of interest.
References
1] C.J. Meijer, J. Berkhof, P.E. Castle, A.T. Hesselink, E.L. Franco, G. Ronco, M. Arbyn,
F.X. Bosch, J. Cuzick, J. Dillner, D.A. Heideman, P.J. Snijders, Guidelines for
human papillomavirus DNA test requirements for primary cervical cancer
screening in women 30 years and older, Int. J. Cancer 124 (2009) 516–520.
2] C.J. Meijer, H. Berkhof, D.A. Heideman, A.T. Hesselink, P.J. Snijders, Validation of
high-risk HPV tests for primary cervical screening, J. Clin. Virol. 46 (Suppl. 3)
(2009) S1–S4.
3] M.  Arbyn, P.J. Snijders, C.J. Meijer, J. Berkhof, K. Cuschieri, B.J. Kocjan, M.  Poljak,
Which high-risk HPV assays fulﬁl criteria for use in primary cervical cancer
screening? Clin. Microbiol. Infect. 21 (2015) 817–826.
4] M.J. Kwon, K.H. Roh, H. Park, H.Y. Woo, Comparison of the anyplex II HPV28
assay with the hybrid capture 2 assay for the detection of HPV infection, J. Clin.
Virol. 59 (2014) 246–249.
5] P.J.F. Snijders, A.J.C. Van den Brule, M.V. Jacobs, R.P. Pol, C.J.L.M. Meijer, HPV
DNA detection and typing in cervical scrapes by general primer GP5+/6+PCR,Papillomaviruses-Methods and Protocols, vol. 119, Humana Press, Totowa,
USA, 2005, pp. 101–114.
6] N.S. Tang, M.L. Tang, I.S. Chan, On tests of equivalence via non-unity relative
risk for matched-pair design, Stat. Med. 22 (2003) 1217–1233.
